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To the Editor:
Axenfeld-Rieger Syndrome (ARS) (OMIM 602482) is a rare
developmental disorder characterized by anterior segment dysgene-
sis, affecting the peripheral cornea and iris, and iridocorneal angle. Iris
attachments to the posterior embryotoxon (prominent Schwalbe’s
line) in both eyes characterize ARS patients. Other iris findings might
include stromal thinning or atrophy, corectopia, iris holes, and
ectropion uvea. A major consequence of the anterior segment
dysgenesis is increased intraocular pressure, leading to glaucoma, in
approximately half of the ARS patients. Extraocular findings in ARS
are also present and may include craniofacial anomalies such as
maxillary and occasionally mandibular hypoplasia, hypertelorism,
telecanthus, micro-hypodontia, cardiovascular malformations, anom-
alies of the pituitary gland, growth hormone deficiency, genitourinary
anomalies like hypospadias in males, or periumbilical skin redundancy
(Chang, Summers, Schimmenti, & Grajewski, 2012; Tumer & Bach-
Holm, 2009).
Other disorders may have phenotypic overlapping with ARS, such
as hypoplasia/iridogoniodysgenesis anomaly/syndrome, Peters anom-
aly, and infantile/primary congenital glaucoma (Tumer & Bach-Holm,
2009). The most important disorder to consider is Peters anomaly, an
iridogoniodysgenesis, usually bilateral, appearing in the sameage group.
Patients with this disease may also present posterior embryotoxon, iris
coloboma, aniridia, and glaucoma, as in ARS patients. However, the
disease is characterized by the presence of one or more central corneal
opacities caused by central absence of the corneal endothelium,
Descemet’s membrane and posterior corneal stroma. The central
corneal opacities are absent in ARS (Weisschuh, Wolf, Wissinger, &
Gramer, 2008).
ARS is an autosomal dominant disordermainly affecting eyewith a
genetic heterogeneity and estimated prevalence of 1 in 200,000. It is
associated with mutations and copy number changes in two
transcription factor genes: PITX2 (Semina et al., 1996), and FOXC1
(Mears et al., 1998). PITX2 is mutated more commonly in patients with
dental and/or umbilical anomalies while FOXC1 mutations are
revealed more frequently in cases with isolated ocular findings or in
association with heart and/or hearing defects (Reis et al., 2012).
Sporadic cases have also been reportedwithCYP1B1 (Tanwar, Dada, &
Dada, 2010), and PRDM5 mutations (Micheal et al., 2016).
In this study, we report on a 14-month-old Portuguese male
presenting with typical features of ARS (Table 1, Figure 1), including
bilateral glaucoma. No anterior segment anomalies were present in the
parents. Hypertelorism, maxillary hypoplasia, dental anomalies, and
short stature (below 3rd centiles [World Health Organization, 2009])
led to the preliminary diagnosis of ARS. The boy also had frontal
prominence, broad nasal root, and unilateral testicular atrophy.
Neither cardiac malformations, also confirmed by normal echocardi-
ography, nor redundant periumbilical skin were present. At 23 months
of age, growth hormone, and IGF1 levels were in normal limits and
his growth parameters and neuromotor developmentwere reported as
normal.
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The family provided informed consent for research and publica-
tion in act to Helsinki Declaration. Whole-exome sequencing was
performed on genomic DNA of the proband using Ion AmpliSeq™ RDY
Exome Kit with the Ion Proton System (Life Technologies). After the
run, the sequences were aligned to the hg19/GRCh37 reference
genome and the variants annotated by ANNOVAR. SNPs and Indels
were filtered to identify the disease-causing variant and the related
gene. Exonic and splice-site variants were selected for minor allele
frequency (MAF) inferior to 1%, according to the information in the
European population of the 1,000 Genome Project, NHLBI Exome
Sequencing Project and an in-house database. Functional impact of
the remaining variants was evaluated based on the scores provided by
SIFT, PolyPhen-2, MutationTaster, and CADD software. Inter-species
conservation scores were provided by PhyloP and GERP++ software.
The genes related with ARS phenotype, FOXC1, PIXT2, CYP1B1,
and PRDM5, were considered as possible candidate genes and
analysed to identify causal pathogenic variants. The patient presented
the heterozygous nonsense variant p.Tyr64Ter (c.192 C > G) in FOXC1
(Figure 2). No other variants were identified in the 3′UTR of this gene
or in the coding regions of PITX2, CYP1B1, and PRDM5. The FOXC1
variant, c.192 C > G, was further confirmed by Sanger sequencing in
the proband and excluded in the parents revealing de novo state for
autosomal dominant inheritance pattern. The mutation was not
observed in public databases neither in a Portuguese control
population.
The in silico functional impact evaluated by MutationTaster
classified the variant as “disease causing” and the CADD software
indicated a high scaled score of 36, suggesting the deleterious effect
of the mutation. This p.Tyr64Ter mutation is located before the
DNA-binding forkhead domain (FHD) (Figure 2c), resulting in a
truncated protein composed only of the activation domain with loss
of 88.6% of the protein. Consequently, the FHD, the inhibition
TABLE 1 Biometric parameters revealed by detailed opthalmological examination
Parameters Right eye Left eye
Horizontal corneal diameter (mm) 14 13
Vertical corneal diameter (mm) 13.5 13
Axial length (mm) 21.61 21.26
Anterior chamber (mm) 3.96 3.67
IOP (mmHg, by Perkins tonometer, under anesthesia, and maleate timolol) 20 18
US central corneal thickness 656 612
Haab striae Yes No
Posterior embryotoxon Yes Yes
Iridocorneal extensions Yes Yes
Cup/disc Large disc and large cup Large disc and large cup
IOP, intraocular pressure; US, ultrasound.
Note that posterior embryotoxon, iridocorneal extensionswere present in both eyes. Corneal diameter, central corneal thickness, anterior chamber, and axial
lengthwere increased in both eyes. High intraocular pressurewas noted bilaterally while Haab striae was observed only in the right eye. Normative values for
the biometric parameters are in supplementary material S1.
FIGURE 1 Ocular and dental changes observed in the proband. (a) Embryotoxon (white arrows). (b) Iridocorneal angle showing iridocorneal
extensions (yellow arrow). (c) Haab Striae (green arrows). (d) Microdontia. [Color figure can be viewed at wileyonlinelibrary.com]
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domain, and the activation domain two will be absent. In a recent
study, Medina-Trillo and collaborators described an increased
transactivation activity in two nonsense mutations: p.Tyr47Ter and
p.Gln106Ter. Similar to the mutation revealed in our patient,
p.Tyr47Ter also resides before the FHD. The authors suggested
that this unexpected gain-of-function might be related to the
isolated expression of the activation domain 1, without the inhibitor
domain. The activation domain 1 appears to act as a potent and
independent transcription up-regulator that can interact with other
transcription factors beyond FOXC1 (Medina-Trillo et al., 2015).
According to this data, we hypothesize that the de novo mutation
identified in our study can create a hypermorphic allele, being
responsible for the ARS phenotype observed in the patient.
The mechanism behind the development of glaucoma caused by
FOXC1 disruption is not clearly understood. This transcription factor is
expressed during eye organogenesis in the periocular mesenchyme,
trabecular meshwork, sclera, and conjunctival epithelium (Kidson,
Kume, Deng, Winfrey, & Hogan, 1999). It has a significant role in the
normal corneal development, preserving corneal transparency by
regulating vascular growth, and is also involved in the correct iris and
trabecular meshwork formation (Kidson et al., 1999; Seo et al., 2012).
Studies performed in human trabecular meshwork (TM) cells revealed
the important role of FOXC1 in the response to oxidative stress and
FOXC1 dysregulation results in TM cell death. The loss of TM
cellularity will prevent aqueous humor uptake with a consequent
increase in intraocular pressure (IOP), a major risk factor for the
development of glaucoma (Berry et al., 2008; Ito, Goping, Berry, &
Walter, 2014).
In addition to the candidate approach, all exonic and splice site
variants, excluding synonymous variants, were evaluated for patho-
genicity according to ClinVar database classification or for association
with a disease on the GWAS catalog. The purpose of this analysis was
to find possible associations between the other variants and the
patient’s features. A commonpreviously described variant inCOL11A1
identified by GWAS as a susceptibility locus for primary angle closure
glaucoma (PACG) (Vithana et al., 2012) was also found at heterozygote
state in the patient: p.Pro1323Leu (c.3968C > T, rs3753841).
COL11A1 encodes the alpha chain of collagen type XI and pathogenic
mutations in this gene are causative of syndromes with ocular
involvement. This protein is a component of the extracellular matrix of
human TM and, therefore, contributes to its structure (Acott & Kelley,
2008; Vithana et al., 2012). Despite rs3753841 being predicted to
have a moderate effect on the protein, a small aberrant activity or
expression, in the presence of the hypermorphic FOXC1 allele, could
contribute to a disruption of the TM and aqueous humor drainagewith
IOP increase. Further studies will clarify the possible impact of this
variant in association with FOXC1 in the pathogenesis of glaucoma in
ARS patients.
In conclusion, molecular screening by WES for ARS which has
genetic heterogeneity has led to the identification of a novel nonsense
mutation in FOXC1. This variant expanded the spectrum of FOXC1
mutations associated with ARS. WES leads to fast, easy screening of
several genes simultaneously to identify genetic etiopathogenesis and
in cases where surveillance and treatment strategies are based on
molecular data could be considered as the first tier testing.
Furthermore, WES analysis may provide additional data on accompa-
nying variants which may also have an impact on the clinical
phenotype.
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FIGURE 2 (a) Pedigree of the family and Sanger sequencing electropherograms showing c.192 C > G (p.Tyr64Ter) FOXC1 mutation at
heterozygote state in the proband and wild-type allele in both parents. (b) Multiple amino acid alignment of the FOXC1 protein of known
vertebrates. The novel mutation p.Tyr64Ter occurs in a highly conserved amino acid across the species. Alignments were performed with
Clustal Omega. (c) Localization of the p.Tyr64Ter FOXC1 mutation before the forkhead domain and overview of FOXC1 mutations. AD-1:
activation domain 1; AD-2: activation domain 2; NSL1: nuclear localization signal 1; NSL2: nuclear localization signal 2
CARMONA ET AL. | 1609
para a Ciência e a Tecnologia (SFRH/BD/9044/2012), Programa
Operacional Potencial Humano/Fundo Social Europeu (POPH/FSE).
CONFLICTS OF INTEREST
The authors report no competing, commercial, or conflicts of interests.
The authors are responsible for the content and writing of the paper.
REFERENCES
Acott, T. S., & Kelley, M. J. (2008). Extracellular matrix in the trabecular
meshwork. Experimental Eye Research, 86(4), 543–561.
Berry, F. B., Skarie, J. M., Mirzayans, F., Fortin, Y., Hudson, T. J., Raymond,
V., . . . Walter, M. A. (2008). FOXC1 is required for cell viability and
resistance to oxidative stress in the eye through the transcriptional
regulation of FOXO1A. Human Molecular Genetics, 17(4), 490–505.
Chang, T. C., Summers, C. G., Schimmenti, L. A., & Grajewski, A. L. (2012).
Axenfeld-Rieger syndrome: New perspectives. British Journal of
Ophthalmology, 96(3), 318–322.
Ito, Y. A., Goping, I. S., Berry, F., & Walter, M. A. (2014). Dysfunction of
the stress-responsive FOXC1 transcription factor contributes to
the earlier-onset glaucoma observed in Axenfeld-Rieger syndrome
patients. Cell Death & Disease, 5, e1069.
Kidson, S. H., Kume, T., Deng, K., Winfrey, V., & Hogan, B. L. (1999). The
forkhead/winged-helix gene, Mf1, is necessary for the normal
development of the cornea and formation of the anterior chamber in
the mouse eye. Developmental Biology, 211(2), 306–322.
Mears, A. J., Jordan, T., Mirzayans, F., Dubois, S., Kume, T., Parlee, M., . . .
Walter, M. A. (1998). Mutations of the forkhead/winged-helix gene,
FKHL7, in patients with Axenfeld-Rieger anomaly. American Journal of
Human Genetics, 63(5), 1316–1328.
Medina-Trillo, C., Sanchez-Sanchez,F., Aroca-Aguilar, J.D., Ferre-Fernandez,
J. J., Morales, L., Mendez-Hernandez, C. D., . . . Escribano, J. (2015).
Hypo- and hypermorphic FOXC1 mutations in dominant glaucoma:
Transactivation and phenotypic variability. PLoS ONE, 10(3), e0119272.
Micheal, S., Siddiqui, S. N., Zafar, S. N., Venselaar, H., Qamar, R., Khan, M. I.,
& den Hollander, A. I. (2016). Whole exome sequencing identifies a
heterozygous missense variant in the PRDM5 gene in a family with
Axenfeld-Rieger syndrome. Neurogenetics, 17(1), 17–23.
Reis, L. M., Tyler, R. C., Volkmann Kloss, B. A., Schilter, K. F., Levin, A. V.,
Lowry, R. B., . . . Semina, E. V. (2012). PITX2 and FOXC1 spectrum of
mutations in ocular syndromes. European Journal of Human Genetics,
20(12), 1224–1233.
Semina, E. V., Reiter, R., Leysens, N. J., Alward, W. L., Small, K. W., Datson,
N. A., . . . Murray, J. C. (1996). Cloning and characterization of a novel
bicoid-related homeobox transcription factor gene, RIEG, involved in
Rieger syndrome. Nature Genetics, 14(4), 392–399.
Seo, S., Singh, H. P., Lacal, P. M., Sasman, A., Fatima, A., Liu, T., . . . Kume, T.
(2012). Forkhead box transcription factor FoxC1 preserves corneal
transparency by regulating vascular growth. Proceedings of the National
Academy of Sciences of the United States of America, 109(6), 2015–2020.
Tanwar, M., Dada, T., & Dada, R. (2010). Axenfeld-Rieger syndrome
associated with congenital glaucoma and cytochrome P4501B1 gene
mutations. Case Reports in Medicine, 2010.
Tumer, Z., & Bach-Holm, D. (2009). Axenfeld-Rieger syndrome and
spectrum of PITX2 and FOXC1 mutations. European Journal of Human
Genetics, 17(12), 1527–1539.
Vithana, E. N., Khor, C. C., Qiao, C., Nongpiur, M. E., George, R., Chen, L. J.,
. . . Aung, T. (2012). Genome-wide association analyses identify three
new susceptibility loci for primary angle closure glaucoma. Nature
Genetics, 44(10), 1142–1146.
Weisschuh, N., Wolf, C., Wissinger, B., & Gramer, E. (2008). A novel
mutation in the FOXC1 gene in a family with Axenfeld-Rieger
syndrome and Peters’ anomaly. Clinical Genetics, 74(5), 476–480.
World Health Organization, United Nations Children’s Fund. 2009. WHO
child growth standards and the identification of severe acute
malnutrition in infants and children: A Joint Statement. World Health
Organization.
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the
supporting information tab for this article.
How to cite this article: Carmona S, da Luz Freitas M,
Froufe H, et al. Novel de novo FOXC1 nonsense mutation in
an Axenfeld-Rieger syndrome patient. Am J Med Genet Part A.
2017;173A:1607–1610. https://doi.org/10.1002/ajmg.a.38234
1610 | CARMONA ET AL.
